Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVeris completes infectious vaccine license
The agreement includes the rights to use Neisseria meningitidis group Y and Haemophilus influenzae type b (Hib) components for the new vaccines These new vaccine candidates are expected
The agreement includes the rights to use Neisseria meningitidis group Y and Haemophilus influenzae type b (Hib) components for the new vaccines These new vaccine candidates are expected
The ruling involves a patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, which expires in July 2010. Pfizer said that the ruling on the
“The continued advancement of the HIF-1 alpha program demonstrates our commitment to developing a differentiated cancer portfolio,” said Jeffrey Buchalter, chairman and CEO of Enzon. HIF-1 alpha is
Following the conclusion of the review, the opinion for Januvia will be transmitted to the European Commission (EC). If the EC adopts the opinion, Januvia will be the
The European Commission is expected to issue a final decision within approximately six weeks. Xyrem has been designated as an orphan medicinal product. Orphan medicinal products are used
The studies, designed to expand the use of the drug, included examining the effectiveness of the drug in patients undergoing elective spinal fusion surgery, pneumonectomy or esophagectomy for
The trial will compare treatment with galiximab in combination with rituximab(Genentech/Biogen Idec's Rituxan), to rituximab in combination with placebo in patients with follicular non-Hodgkin's lymphoma (NHL) that has
P53 plays critical role in the development of many tumors and it is mutated in many cancers. Researchers have identified compounds that restore p53 , but it has
In addition, the data validates VLA-2 as a potential target for early therapeutic intervention in the treatment of multiple sclerosis (MS). “Currently, there are no FDA approved therapies
Peramivir is in clinical development for the treatment of seasonal and potentially life-threatening human influenza. Two different doses of peramivir will be tested. “The safety and antiviral activity